Ragini Medhi

Ragini Medhi

Auto-generated profile, based on publicly available information

Ragini Medhi

Cancer Research Horizons, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
AGAaron Goldman
Aaron Goldman
SKSachin Khiste
Sachin Khiste
EFElizaveta Freinkman
Elizaveta Freinkman
ADAndrew Dhawan
Andrew Dhawan
BMBiswanath Majumder
Biswanath Majumder
SSShiladitya Sengupta
Shiladitya Sengupta
Metastable phenotypic state transitions in cancer cells can lead to the development of transient adaptive resistance or tolerance to chemotherapy. Here, we report that the acquisition of a phenotype marked by increased abundance of CD44 (CD44Hi) by breast cancer cells as a tolerance response to routinely used cytotoxic drugs, such as taxanes, activated a metabolic switch that conferred tolerance against unrelated standard-of-care chemotherapeutic agents, such as anthracyclines. We characterized the sequence of molecular events that connected the induced CD44Hi phenotype to increased activity of both the glycolytic and oxidative pathways and glucose flux through the pentose phosphate pathway (PPP). When given in a specific order, a combination of taxanes, anthracyclines, and inhibitors of glucose-6-phosphate dehydrogenase (G6PD), an enzyme involved in glucose metabolism, improved survival in mouse models of breast cancer. The same sequence of the three-drug combination reduced the viability of patient breast tumor samples in an explant system. Our findings highlight a convergence between phenotypic and metabolic state transitions that confers a survival advantage to cancer cells against clinically used drug combinations. Pharmacologically targeting this convergence could overcome cross-drug tolerance and could emerge as a new paradigm in the treatment of cancer.

21 November 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
FVFanny Volat
Fanny Volat
RMRagini Medhi
Ragini Medhi
LMLauren Z. Maggs
Lauren Z. Maggs
MDMarcel A. Deken
Marcel A. Deken
APAlice Price
Alice Price
SFStuart Farrow
Stuart Farrow
Autotaxin (ATX), encoded by ENPP2, is a clinical target in pancreatic ductal adenocarcinoma (PDAC). ATX catalyzes the production of lysophosphatidic acid (LPA), an important regulator within the tumor microenvironment (TME), yet the protumorigenic action of the ATX/LPA axis in PDAC remains unclear. In this study, by interrogating patient samples and cell line datasets, we show that the PDAC TME, rather than cancer cells, is responsible for the majority of ENPP2 expression and highlight a key role for cancer-associated fibroblast (CAF)-derived ATX in autocrine and paracrine protumorigenic signaling. Using the clinical-stage ATX inhibitor, IOA-289, we identified connective tissue growth factor (CTGF), also known as CCN2, as a downstream mediator of ATX signaling in the PDAC CAF-derived cell line, 0082T. Genetic ablation or pharmacologic inhibition of ATX in 0082T CAFs reduced CTGF secretion via modulation of LPA/LPA receptor signaling. Despite the loss of ATX function, extracellular levels of LPA were paradoxically increased, indicating a role for ATX beyond its enzymatic activity and suggesting a role for its LPA chaperone function in the LPA/LPA receptor signaling in CAFs. As CAFs are the main source for CTGF in the PDAC TME, these findings suggest a role for ATX in promoting a protumorigenic microenvironment via modulation of CAF secretion not only via its LPA-producing activity but also via its LPA chaperone function, providing a potential mechanism for the antitumor effects of ATX inhibition.

4 February 2025
Verified
Other
Open access
FVFanny Volat
Fanny Volat
RMRagini Medhi
Ragini Medhi
LMLauren Z. Maggs
Lauren Z. Maggs
MDMarcel A. Deken
Marcel A. Deken
APAlice Price
Alice Price
SFStuart Farrow
Stuart Farrow
Supplementary Figure S1 shows the validation of ESTIMATE stromal and immune gene signatures and mRNA expression in tumour-rich and TME-rich samples.

4 February 2025
Verified
Other
Open access
FVFanny Volat
Fanny Volat
RMRagini Medhi
Ragini Medhi
LMLauren Z. Maggs
Lauren Z. Maggs
MDMarcel A. Deken
Marcel A. Deken
APAlice Price
Alice Price
SFStuart Farrow
Stuart Farrow
Supplementary Table S1 shows the list of Taqman assays used for qPCR experiments.

4 February 2025
Verified
Other
Open access
FVFanny Volat
Fanny Volat
RMRagini Medhi
Ragini Medhi
LMLauren Z. Maggs
Lauren Z. Maggs
MDMarcel A. Deken
Marcel A. Deken
APAlice Price
Alice Price
SFStuart Farrow
Stuart Farrow
Supplementary Figure S5 shows RNA-seq analysis of 0082T CAFs after treatment with ATX inhibitors.

4 February 2025
Verified
Other
Open access
FVFanny Volat
Fanny Volat
RMRagini Medhi
Ragini Medhi
LMLauren Z. Maggs
Lauren Z. Maggs
MDMarcel A. Deken
Marcel A. Deken
APAlice Price
Alice Price
SFStuart Farrow
Stuart Farrow
Supplementary Figure S3 shows ATX antibody validation and ATX detection in cancer and CAF co-cultures.